Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study.

Westin SN, Sill MW, Coleman RL, Waggoner S, Moore KN, Mathews CA, Martin LP, Modesitt SC, Lee S, Ju Z, Mills GB, Schilder RJ, Fracasso PM, Birrer MJ, Aghajanian C.

Gynecol Oncol. 2019 Oct 15. pii: S0090-8258(19)31548-3. doi: 10.1016/j.ygyno.2019.09.024. [Epub ahead of print]

PMID:
31623857
2.

Paclitaxel and Alisertib in Recurrent Ovarian Cancer-In Reply.

Falchook G, Coleman RL, Schilder RJ.

JAMA Oncol. 2019 Jun 1;5(6):910-911. doi: 10.1001/jamaoncol.2019.0562. No abstract available.

PMID:
31021370
3.
4.

Palmitate- and C6 ceramide-induced Tnnt3 pre-mRNA alternative splicing occurs in a PP2A dependent manner.

Black AJ, Schilder RJ, Kimball SR.

Nutr Metab (Lond). 2018 Dec 17;15:87. doi: 10.1186/s12986-018-0326-3. eCollection 2018.

5.

Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial.

Falchook G, Coleman RL, Roszak A, Behbakht K, Matulonis U, Ray-Coquard I, Sawrycki P, Duska LR, Tew W, Ghamande S, Lesoin A, Schwartz PE, Buscema J, Fabbro M, Lortholary A, Goff B, Kurzrock R, Martin LP, Gray HJ, Fu S, Sheldon-Waniga E, Lin HM, Venkatakrishnan K, Zhou X, Leonard EJ, Schilder RJ.

JAMA Oncol. 2019 Jan 1;5(1):e183773. doi: 10.1001/jamaoncol.2018.3773. Epub 2019 Jan 10.

6.

Metformin as a Therapeutic Target in Endometrial Cancers.

Lee TY, Martinez-Outschoorn UE, Schilder RJ, Kim CH, Richard SD, Rosenblum NG, Johnson JM.

Front Oncol. 2018 Aug 28;8:341. doi: 10.3389/fonc.2018.00341. eCollection 2018. Review.

7.

Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor.

Niu H, Shin H, Gao F, Zhang J, Bahamon B, Danaee H, Melichar B, Schilder RJ, Coleman RL, Falchook G, Adenis A, Behbakht K, DeMichele A, Dees EC, Perez K, Matulonis U, Sawrycki P, Huebner D, Ecsedy J.

EBioMedicine. 2017 Nov;25:50-57. doi: 10.1016/j.ebiom.2017.10.015. Epub 2017 Oct 16.

8.
9.
10.

Dietary Fat Quantity and Type Induce Transcriptome-Wide Effects on Alternative Splicing of Pre-mRNA in Rat Skeletal Muscle.

Black AJ, Ravi S, Jefferson LS, Kimball SR, Schilder RJ.

J Nutr. 2017 Sep;147(9):1648-1657. doi: 10.3945/jn.117.254482. Epub 2017 Aug 2.

11.

A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer.

Kristeleit R, Davidenko I, Shirinkin V, El-Khouly F, Bondarenko I, Goodheart MJ, Gorbunova V, Penning CA, Shi JG, Liu X, Newton RC, Zhao Y, Maleski J, Leopold L, Schilder RJ.

Gynecol Oncol. 2017 Sep;146(3):484-490. doi: 10.1016/j.ygyno.2017.07.005. Epub 2017 Jul 8.

PMID:
28698009
12.

A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.

Jandial DA, Brady WE, Howell SB, Lankes HA, Schilder RJ, Beumer JH, Christner SM, Strychor S, Powell MA, Hagemann AR, Moore KN, Walker JL, DiSilvestro PA, Duska LR, Fracasso PM, Dizon DS.

Gynecol Oncol. 2017 May;145(2):236-242. doi: 10.1016/j.ygyno.2017.03.013. Epub 2017 Mar 22.

13.

Brain Metastases in Patients with Gynecologic Cancers: A Single Institution Experience and Review of the Literature.

Gilani MA, Williams NL, Giordano C, Rosenblum N, Shi W, Anne P, Schilder RJ.

Open J Obstet Gynecol. 2016 Aug;6(9):544-552. doi: 10.4236/ojog.2016.69070. Epub 2016 Aug 15.

14.

(How) do animals know how much they weigh?

Schilder RJ.

J Exp Biol. 2016 May 1;219(Pt 9):1275-82. doi: 10.1242/jeb.120410. Review.

15.

Effects of age and hindlimb immobilization and remobilization on fast troponin T precursor mRNA alternative splicing in rat gastrocnemius muscle.

Ravi S, Schilder RJ, Berg AS, Kimball SR.

Appl Physiol Nutr Metab. 2016 Feb;41(2):142-9. doi: 10.1139/apnm-2015-0381. Epub 2015 Oct 16.

16.

A Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian Cancer.

Pathak HB, Zhou Y, Sethi G, Hirst J, Schilder RJ, Golemis EA, Godwin AK.

PLoS One. 2015 Dec 4;10(12):e0144126. doi: 10.1371/journal.pone.0144126. eCollection 2015.

17.

A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma.

Amaravadi RK, Schilder RJ, Martin LP, Levin M, Graham MA, Weng DE, Adjei AA.

Mol Cancer Ther. 2015 Nov;14(11):2569-75. doi: 10.1158/1535-7163.MCT-15-0475. Epub 2015 Sep 2.

18.

Influence of ageing and essential amino acids on quantitative patterns of troponin T alternative splicing in human skeletal muscle.

Coble J, Schilder RJ, Berg A, Drummond MJ, Rasmussen BB, Kimball SR.

Appl Physiol Nutr Metab. 2015 Aug;40(8):788-796. doi: 10.1139/apnm-2014-0568. Epub 2015 Mar 23.

19.

Hereditary ovarian cancer: not only BRCA 1 and 2 genes.

Toss A, Tomasello C, Razzaboni E, Contu G, Grandi G, Cagnacci A, Schilder RJ, Cortesi L.

Biomed Res Int. 2015;2015:341723. doi: 10.1155/2015/341723. Epub 2015 May 17. Review.

20.

Role of precursor mRNA splicing in nutrient-induced alterations in gene expression and metabolism.

Ravi S, Schilder RJ, Kimball SR.

J Nutr. 2015 May;145(5):841-6. doi: 10.3945/jn.114.203216. Epub 2015 Mar 11. Review.

21.

Adjuvant vaginal cuff brachytherapy for high-risk, early stage endometrial cancer.

Eldredge-Hindy HB, Eastwick G, Anne PR, Rosenblum NG, Schilder RJ, Chalian R, Zibelli AM, Kim CH, Den R.

J Contemp Brachytherapy. 2014 Oct;6(3):262-70. doi: 10.5114/jcb.2014.45031. Epub 2014 Sep 5.

22.

A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.

Vergote I, Schilder RJ, Pippitt CH Jr, Wong S, Gordon AN, Scudder S, Kridelka F, Dirix L, Leach JW, Ananda S, Nanayakkara N, Melara R, Bass MB, Litten J, Adewoye H, Wenham RM.

Gynecol Oncol. 2014 Oct;135(1):25-33. doi: 10.1016/j.ygyno.2014.07.003. Epub 2014 Jul 11.

23.

Refractory fallopian tube carcinoma - current perspectives in pathogenesis and management.

Sama AR, Schilder RJ.

Int J Womens Health. 2014 Jan 28;6:149-57. doi: 10.2147/IJWH.S40889. eCollection 2014. Review.

24.

De novo transcriptome assembly from fat body and flight muscles transcripts to identify morph-specific gene expression profiles in Gryllus firmus.

Nanoth Vellichirammal N, Zera AJ, Schilder RJ, Wehrkamp C, Riethoven JJ, Brisson JA.

PLoS One. 2014 Jan 8;9(1):e82129. doi: 10.1371/journal.pone.0082129. eCollection 2014.

25.

Influence of bevacizumab on vaginal cuff evisceration eight months after ovarian cancer cytoreduction surgery: A case report.

Skwara AJ, Schilder RJ, Zibelli A, Rosenblum NG.

Gynecol Oncol Case Rep. 2013 Jul 1;6:7-9. doi: 10.1016/j.gynor.2013.06.005. eCollection 2013.

26.

A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Martin LP, Sill M, Shahin MS, Powell M, DiSilvestro P, Landrum LM, Gaillard SL, Goodheart MJ, Hoffman J, Schilder RJ.

Gynecol Oncol. 2014 Mar;132(3):526-30. doi: 10.1016/j.ygyno.2013.12.018. Epub 2013 Dec 18.

27.

Potential role of mTORC2 as a therapeutic target in clear cell carcinoma of the ovary.

Hisamatsu T, Mabuchi S, Matsumoto Y, Kawano M, Sasano T, Takahashi R, Sawada K, Ito K, Kurachi H, Schilder RJ, Testa JR, Kimura T.

Mol Cancer Ther. 2013 Jul;12(7):1367-77. doi: 10.1158/1535-7163.MCT-12-1185. Epub 2013 Apr 24.

28.

Genetic variation in HIF signaling underlies quantitative variation in physiological and life-history traits within lowland butterfly populations.

Marden JH, Fescemyer HW, Schilder RJ, Doerfler WR, Vera JC, Wheat CW.

Evolution. 2013 Apr;67(4):1105-15. doi: 10.1111/evo.12004. Epub 2012 Dec 11.

PMID:
23550759
29.

A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study.

Leslie KK, Sill MW, Fischer E, Darcy KM, Mannel RS, Tewari KS, Hanjani P, Wilken JA, Baron AT, Godwin AK, Schilder RJ, Singh M, Maihle NJ.

Gynecol Oncol. 2013 Jun;129(3):486-94. doi: 10.1016/j.ygyno.2013.02.019. Epub 2013 Feb 21.

30.

Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion.

Do TV, Xiao F, Bickel LE, Klein-Szanto AJ, Pathak HB, Hua X, Howe C, O'Brien SW, Maglaty M, Ecsedy JA, Litwin S, Golemis EA, Schilder RJ, Godwin AK, Connolly DC.

Oncogene. 2014 Jan 30;33(5):539-49. doi: 10.1038/onc.2012.632. Epub 2013 Jan 21.

31.

A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study.

Schilder RJ, Sill MW, Lankes HA, Gold MA, Mannel RS, Modesitt SC, Hanjani P, Bonebrake AJ, Sood AK, Godwin AK, Hu W, Alpaugh RK.

Gynecol Oncol. 2013 Apr;129(1):86-91. doi: 10.1016/j.ygyno.2013.01.006. Epub 2013 Jan 13.

32.

The mTORC1 signaling repressors REDD1/2 are rapidly induced and activation of p70S6K1 by leucine is defective in skeletal muscle of an immobilized rat hindlimb.

Kelleher AR, Kimball SR, Dennis MD, Schilder RJ, Jefferson LS.

Am J Physiol Endocrinol Metab. 2013 Jan 15;304(2):E229-36. doi: 10.1152/ajpendo.00409.2012. Epub 2012 Nov 27.

33.

Ovarian cancer, version 3.2012.

Morgan RJ Jr, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Santoso JT, Schilder RJ, Schink J, Teng N, Werner TL, Hughes M, Dwyer MA; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2012 Nov 1;10(11):1339-49.

PMID:
23138163
34.

A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study.

Moore KN, Sill MW, Miller DS, McCourt C, De Geest K, Rose PG, Cardenes HR, Mannel RS, Farley JH, Schilder RJ, Fracasso PM.

Gynecol Oncol. 2012 Dec;127(3):456-61. doi: 10.1016/j.ygyno.2012.08.030. Epub 2012 Sep 7.

PMID:
22960004
35.

Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.

Leslie KK, Sill MW, Lankes HA, Fischer EG, Godwin AK, Gray H, Schilder RJ, Walker JL, Tewari K, Hanjani P, Abulafia O, Rose PG.

Gynecol Oncol. 2012 Nov;127(2):345-50. doi: 10.1016/j.ygyno.2012.07.127. Epub 2012 Aug 7.

36.

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.

Matulonis UA, Sharma S, Ghamande S, Gordon MS, Del Prete SA, Ray-Coquard I, Kutarska E, Liu H, Fingert H, Zhou X, Danaee H, Schilder RJ.

Gynecol Oncol. 2012 Oct;127(1):63-9. doi: 10.1016/j.ygyno.2012.06.040. Epub 2012 Jul 5.

PMID:
22772063
37.

Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Schilder RJ, Brady WE, Lankes HA, Fiorica JV, Shahin MS, Zhou XC, Mannel RS, Pathak HB, Hu W, Alpaugh RK, Sood AK, Godwin AK.

Gynecol Oncol. 2012 Oct;127(1):70-4. doi: 10.1016/j.ygyno.2012.06.009. Epub 2012 Jun 16.

38.

Cell-autonomous regulation of fast troponin T pre-mRNA alternative splicing in response to mechanical stretch.

Schilder RJ, Kimball SR, Jefferson LS.

Am J Physiol Cell Physiol. 2012 Aug 1;303(3):C298-307. doi: 10.1152/ajpcell.00400.2011. Epub 2012 May 16.

39.

Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.

Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, Schilder RJ, Cai KQ, Godwin AK, Alpaugh RK.

Gynecol Oncol. 2011 Oct;123(1):19-26. doi: 10.1016/j.ygyno.2011.06.022. Epub 2011 Jul 12.

40.
41.

A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial.

Schilder RJ, Blessing JA, Shahin MS, Miller DS, Tewari KS, Muller CY, Warshal DP, McMeekin S, Rotmensch J.

Int J Gynecol Cancer. 2010 Oct;20(7):1137-41.

42.
43.

Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study.

Farley J, Sill MW, Birrer M, Walker J, Schilder RJ, Thigpen JT, Coleman RL, Miller BE, Rose PG, Lankes HA.

Gynecol Oncol. 2011 May 1;121(2):303-8. doi: 10.1016/j.ygyno.2011.01.030. Epub 2011 Feb 16.

44.

A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer.

Bell-McGuinn KM, Matthews CM, Ho SN, Barve M, Gilbert L, Penson RT, Lengyel E, Palaparthy R, Gilder K, Vassos A, McAuliffe W, Weymer S, Barton J, Schilder RJ.

Gynecol Oncol. 2011 May 1;121(2):273-9. doi: 10.1016/j.ygyno.2010.12.362. Epub 2011 Jan 26.

45.

Epithelial ovarian cancer.

Morgan RJ Jr, Alvarez RD, Armstrong DK, Boston B, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray HJ, Grigsby PW, Hakam A, Havrilesky LJ, Johnston C, Lele S, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Schilder RJ, Schink JC, Teng N, Werner TL; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2011 Jan;9(1):82-113. No abstract available.

PMID:
21233246
46.

Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium.

Welch SA, Hirte HW, Elit L, Schilder RJ, Wang L, Macalpine K, Wright JJ, Oza AM.

Int J Gynecol Cancer. 2010 Jul;20(5):787-93. doi: 10.1111/IGC.0b013e3181e273a8.

PMID:
20847613
47.

A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.

Aghajanian C, Blessing JA, Darcy KM, Reid G, DeGeest K, Rubin SC, Mannel RS, Rotmensch J, Schilder RJ, Riordan W; Gynecologic Oncology Group.

Gynecol Oncol. 2009 Nov;115(2):215-20. doi: 10.1016/j.ygyno.2009.07.023. Epub 2009 Aug 26.

PMID:
19712963
48.

mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary.

Mabuchi S, Kawase C, Altomare DA, Morishige K, Sawada K, Hayashi M, Tsujimoto M, Yamoto M, Klein-Szanto AJ, Schilder RJ, Ohmichi M, Testa JR, Kimura T.

Clin Cancer Res. 2009 Sep 1;15(17):5404-13. doi: 10.1158/1078-0432.CCR-09-0365. Epub 2009 Aug 18.

49.

A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.

Schilder RJ, Sill MW, Lee YC, Mannel R.

Int J Gynecol Cancer. 2009 Jul;19(5):929-33. doi: 10.1111/IGC.0b013e3181a83467.

50.

Management of recurrent ovarian carcinoma: current status and future directions.

Martin LP, Schilder RJ.

Semin Oncol. 2009 Apr;36(2):112-25. doi: 10.1053/j.seminoncol.2008.12.003. Review.

PMID:
19332246

Supplemental Content

Loading ...
Support Center